Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 84 Lung Neoplasms 39 Carcinoma, Hepatocellular 38 Small Cell Lung Carcinoma 26 Breast Neoplasms 19 Neoplasms 18 Cholangiocarcinoma 18 Urinary Bladder Neoplasms 17 Colorectal Neoplasms 15 Triple Negative Breast Neoplasms 13 Squamous Cell Carcinoma of Head and Neck 12 Pancreatic Neoplasms 10 Liver Neoplasms 10 Biliary Tract Neoplasms 10 Recurrence 9 Ovarian Neoplasms 9 Neoplasm Metastasis 9 Esophageal Neoplasms 8 Carcinoma, Renal Cell 8 Stomach Neoplasms 7 Head and Neck Neoplasms 7 Carcinoma, Transitional Cell 7 Prostatic Neoplasms 6 Melanoma 6 Endometrial Neoplasms 6 Bile Duct Neoplasms 6 Uterine Cervical Neoplasms 5 Neoplasms by Site 5 Mesothelioma, Malignant 5 Adenocarcinoma 5

Interventions

tislelizumab 2 Oxaliplatin 2 tremelimumab 1 olaparib 1 durvalumab 1 apatinib 1 Tegafur 1 Dacarbazine 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Immunotherapy × durvalumab × Clear all

NCT04169841 2024-02-13

GUIDE2REPAIR

Centre Georges Francois Leclerc

Phase 2 Active not recruiting

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡